JP Morgan Chase
CADL icon

JP Morgan Chase’s Candel Therapeutics CADL Stock Holding History

JP Morgan Chase’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$111K Buy
24,863
+3,237
+15% +$17.6K ﹤0.01% 5775
2025
Q4 		$122K Buy
21,626
+3,792
+21% +$20.4K ﹤0.01% 5781
2025
Q3 		$91K Sell
17,834
-1,699
-9% -$9.82K ﹤0.01% 5955
2025
Q2 		$98.8K Buy
19,533
+5,270
+37% +$27.1K ﹤0.01% 5613
2025
Q1 		$80.6K Buy
14,263
+3,837
+37% +$31.4K ﹤0.01% 5669
2024
Q4 		$90.5K Buy
10,426
+1,375
+15% +$8.13K ﹤0.01% 5794
2024
Q3 		$62.7K Sell
9,051
-10,307
-53% -$64K ﹤0.01% 5911
2024
Q2 		$120K Buy
19,358
+19,137
+8,659% +$144K ﹤0.01% 5428
2024
Q1 		$349 Buy
221
+12
+6% +$18 ﹤0.01% 6757
2023
Q4 		$307 Buy
209
+6
+3% +$6 ﹤0.01% 7006
2023
Q3 		$189 Buy
203
+17
+9% +$20 ﹤0.01% 6842
2023
Q2 		$234 Hold
186
– – ﹤0.01% 6620
2023
Q1 		$0 Hold
186
– – ﹤0.01% 6720
2022
Q4 		$0 Sell
186
-1,272
-87% -$2.52K ﹤0.01% 6572
2022
Q3 		$5K Buy
1,458
+211
+17% +$715 ﹤0.01% 6085
2022
Q2 		$4K Sell
1,247
-2,140
-63% -$8.57K ﹤0.01% 6196
2022
Q1 		$17K Buy
3,387
+858
+34% +$4.26K ﹤0.01% 6101
2021
Q4 		$20K Buy
+2,529
New +$24.6K ﹤0.01% 6212

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase's CADL Position: Q1 2026 in Review

JP Morgan Chase increased its Candel Therapeutics (CADL) stake by 15% in Q1 2026, buying an estimated $17.6K and bringing the position to 24,863 shares worth $111K. The position accounts for ﹤0.01% of the portfolio, ranked #5775.

JP Morgan Chase first reported a position in CADL in Q4 2021 and has held it in 18 quarters since. The position peaked at $122K in Q4 2025. 114 funds tracked by Wall St. Rank hold CADL as of Q1 2026.

  • JP Morgan Chase held 24,863 shares of Candel Therapeutics worth $111K as of Q1 2026.
  • JP Morgan Chase bought 3,237 Candel Therapeutics shares in Q1 2026, an estimated $17.6K.
  • Candel Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #5775 holding.
  • JP Morgan Chase first reported a position in Candel Therapeutics in Q4 2021 and has held it in 18 quarters since.
  • JP Morgan Chase's Candel Therapeutics position peaked at $122K in Q4 2025.
  • 114 funds tracked by Wall St. Rank held Candel Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.